Trial Profile
A randomized, double-blind Phase 2b clinical trial evaluating NOX-H94 versus placebo in anemic ESA-hyporesponsive dialysis patients
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2015
Price :
$35
*
At a glance
- Drugs Lexaptepid pegol (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- 01 Jun 2015 New trial record